Commerzbank Aktiengesellschaft FI Invests $8.21 Million in CVS Health Corporation $CVS

Commerzbank Aktiengesellschaft FI acquired a new stake in CVS Health Corporation (NYSE:CVS) in the 2nd quarter, Holdings Channel.com reports. The institutional investor acquired 79,378 shares of the pharmacy operator’s stock, valued at approximately $8,212,000.

A number of other hedge funds also recently made changes to their positions in CVS. Sei Investments Co. increased its stake in CVS Health by 17.4% during the 2nd quarter. Sei Investments Co. now owns 905,715 shares of the pharmacy operator’s stock worth $62,474,000 after buying an additional 134,535 shares during the period. The Manufacturers Life Insurance Company boosted its position in CVS Health by 1.2% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 1,121,377 shares of the pharmacy operator’s stock valued at $77,353,000 after buying an additional 13,329 shares during the last quarter. Treasurer of the State of North Carolina grew its stake in shares of CVS Health by 1.3% during the second quarter. Treasurer of the State of North Carolina now owns 585,073 shares of the pharmacy operator’s stock valued at $40,358,000 after acquiring an additional 7,588 shares in the last quarter. HUB Investment Partners LLC increased its position in shares of CVS Health by 25.0% during the second quarter. HUB Investment Partners LLC now owns 15,063 shares of the pharmacy operator’s stock worth $1,039,000 after acquiring an additional 3,011 shares during the last quarter. Finally, Alliancebernstein L.P. lifted its stake in shares of CVS Health by 8.0% in the second quarter. Alliancebernstein L.P. now owns 1,609,404 shares of the pharmacy operator’s stock worth $111,017,000 after acquiring an additional 119,439 shares in the last quarter. Hedge funds and other institutional investors own 80.66% of the company’s stock.

CVS Health Price Performance

Shares of CVS opened at $93.99 on Tuesday. CVS Health Corporation has a 52 week low of $69.40 and a 52 week high of $110.68. The company has a current ratio of 0.87, a quick ratio of 0.66 and a debt-to-equity ratio of 0.74. The firm has a market cap of $120.21 billion, a price-to-earnings ratio of 24.87, a PEG ratio of 0.93 and a beta of 0.61. The stock has a 50 day moving average of $102.46 and a 200-day moving average of $88.41.

CVS Health (NYSE:CVS) last posted its quarterly earnings results on Wednesday, August 5th. The pharmacy operator reported $2.58 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.87 by $0.71. The business had revenue of $106.10 billion for the quarter, compared to analyst estimates of $100.03 billion. CVS Health had a return on equity of 13.12% and a net margin of 1.18%.The business’s revenue was up 7.3% compared to the same quarter last year. During the same period in the prior year, the company posted $1.81 EPS. CVS Health has set its FY 2026 guidance at 7.900-8.100 EPS. As a group, analysts forecast that CVS Health Corporation will post 8.02 EPS for the current year.

CVS Health Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Monday, August 3rd. Stockholders of record on Thursday, July 23rd were issued a $0.665 dividend. The ex-dividend date of this dividend was Thursday, July 23rd. This represents a $2.66 annualized dividend and a dividend yield of 2.8%. CVS Health’s payout ratio is 70.37%.

Insider Activity at CVS Health

In related news, Director Larry Robbins sold 1,018,000 shares of the business’s stock in a transaction dated Wednesday, May 20th. The shares were sold at an average price of $93.82, for a total transaction of $95,508,760.00. Following the completion of the sale, the director owned 5,195,261 shares of the company’s stock, valued at $487,419,387.02. This represents a 16.38% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 0.85% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on the company. DA Davidson raised their price objective on CVS Health from $80.00 to $100.00 and gave the company a “buy” rating in a research note on Thursday, May 7th. JPMorgan Chase & Co. raised their price target on shares of CVS Health from $111.00 to $118.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 12th. Cantor Fitzgerald lifted their price target on shares of CVS Health from $100.00 to $110.00 and gave the stock an “overweight” rating in a research note on Tuesday, July 7th. Piper Sandler reiterated an “overweight” rating and set a $113.00 price objective on shares of CVS Health in a research note on Monday, June 1st. Finally, Robert W. Baird set a $107.00 price objective on shares of CVS Health in a report on Thursday, August 6th. Twenty-two analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $106.75.

CVS Health Profile

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.